The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Effect of Sibutramine on Cardiovascular Outcomes in Overweight and Obese Subjects
Open accessAbstract
BACKGROUND: The long-term effects of sibutramine treatment on the rates of cardiovascular events and cardiovascular death among subjects at high cardiovascular risk have not been established. METHODS: We enrolled in our study 10,744 overweight or obese subjects, 55 years of age or older, with preexisting cardiovascular disease, type 2 diabetes mellitus, or both to assess the cardiovascular consequences of weight management with and without sibutramine in subjects at high risk for cardiovascular events. All the subjects received sibutramine in addition to participating in a weight-management program during a 6-week, single-blind, lead-in period, after which 9804 subjects underwent random assignment in a double-blind fashion to sibutramine (4906 subjects) or placebo (4898 subjects). The primary end point was the time from randomization to the first occurrence of a primary outcome event (nonfatal myocardial infarction, nonfatal stroke, resuscitation after cardiac arrest, or cardiovascular death). RESULTS: The mean duration of treatment was 3.4 years. The mean weight loss during the lead-in period was 2.6 kg; after randomization, the subjects in the sibutramine group achieved and maintained further weight reduction (mean, 1.7 kg). The mean blood pressure decreased in both groups, with greater reductions in the placebo group than in the sibutramine group (mean difference, 1.2/1.4 mm Hg). The risk of a primary outcome event was 11.4% in the sibutramine group as compared with 10.0% in the placebo group (hazard ratio, 1.16; 95% confidence interval [CI], 1.03 to 1.31; P=0.02). The rates of nonfatal myocardial infarction and nonfatal stroke were 4.1% and 2.6% in the sibutramine group and 3.2% and 1.9% in the placebo group, respectively (hazard ratio for nonfatal myocardial infarction, 1.28; 95% CI, 1.04 to 1.57; P=0.02; hazard ratio for nonfatal stroke, 1.36; 95% CI, 1.04 to 1.77; P=0.03). The rates of cardiovascular death and death from any cause were not increased. CONCLUSIONS: Subjects with preexisting cardiovascular conditions who were receiving long-term sibutramine treatment had an increased risk of nonfatal myocardial infarction and nonfatal stroke but not of cardiovascular death or death from any cause. (Funded by Abbott; ClinicalTrials.gov number, NCT00234832.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Early weight loss medications, such as fenfluramine (Fen-Phen) and sibutramine, were withdrawn due to severe cardiovascular and psychiatric side effects [3,4].”
From Obesity: Clinical Impact, Pathophysiology, Complications, and Modern Innovations in Therapeutic Strategies (2025) · cites this paper as [4]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Despite 5–10% weight loss in trials, it was discontinued in 2010 after the SCOUT trial showed elevated cardiovascular events (e.g., stroke) in high-risk patients [4].”
From Obesity: Clinical Impact, Pathophysiology, Complications, and Modern Innovations in Therapeutic Strategies (2025) · cites this paper as [4]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“the concept of treating obesity to reduce the risk of cardiovascular complications has been hampered by the lack of evidence from trials indicating that lifestyle or pharmacologic interventions for overweight or obesity improve cardiovascular outcomes. 11-15”
From Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (2023) · cites this paper as [13]
In the citing paper
“Prospective studies that evaluated the effect of nonsurgical weight loss interventions on CV event reduction have been disappointing [4, 5, 6, 7, 8].”
From Semaglutide for cardiovascular event reduction in people with overweight or obesity: SELECT study baseline characteristics (2023) · cites this paper as [5]
In the citing paper
“Specifically, across the obesity CVOTs, SELECT is the only study to our knowledge that only enrolled participants with established CVD, whereas in the other obesity CVOTs, 24.9% to 50.5% of participants had no prior events [5, 6, 7, 8].”
From Semaglutide for cardiovascular event reduction in people with overweight or obesity: SELECT study baseline characteristics (2023) · cites this paper as [5]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1998) · New England Journal of Medicine · doi:10.1056/nejm199811053391902 · Cited by 5,261
Prospective Studies Collaboration (2009) · The Lancet · doi:10.1016/s0140-6736(09)60318-4 · Cited by 4,807
Effects of Bariatric Surgery on Mortality in Swedish Obese Subjects
Sjöström, L., Narbro, K., Sjöström, C. D., Karason, K., Larsson, B., Wedel, H., Lystig, T., Sullivan, M., Bouchard, C., Carlsson, B., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066254 · Cited by 4,668
Rubins, H. B., Robins, S. J., Collins, D., Fye, C. L., Anderson, J. W., Elam, M. B., Faas, F. H., Linares, E., Schaefer, E. J., Schectman, G., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199908053410604 · Cited by 3,439
Long-term mortality after gastric bypass surgery
Adams, T. D., Gress, R. E., Smith, S. C., Halverson, R. C., Simper, S. C., Rosamond, W. D., LaMonte, M. J., Stroup, A. M., & Hunt, S. C. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066603 · Cited by 2,572
S UCCESSFUL W EIGHT L OSS M AINTENANCE
Wing, R. R., & Hill, J. O. (2001) · Annual Review of Nutrition · doi:10.1146/annurev.nutr.21.1.323 · Cited by 1,382
Effects of weight reduction on blood lipids and lipoproteins: a meta-analysis
Dattilo, A., & Kris-Etherton, P. (1992) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/56.2.320 · Cited by 1,055
Secular Trends in Cardiovascular Disease Risk Factors According to Body Mass Index in US Adults
Gregg, E. W. (2005) · JAMA · doi:10.1001/jama.293.15.1868 · Cited by 959
Blood Pressure Lowering Treatment Trialists’ Collaboration (2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.12.1410 · Cited by 789
Flagged first, then by citations
Research works printed but not linked: 3
- 1996, Can J Cardiol, 12, 127
- 1994, Lancet, 344, 1383
- Lyznicki JM, 2001, Am Fam Physician, 63, 2185
Cited by
Sorted by citations
Items 101–200 of 943
Norepinephrine transporter function and human cardiovascular disease
Schroeder, C., & Jordan, J. (2012) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00492.2012 · Cited by 109
Dietary supplements as source of unintentional doping
Kozhuharov, V. R., Ivanov, K., & Ivanova, S. (2022) · BioMed Research International · doi:10.1155/2022/8387271 · Cited by 108
Obesity and Cardiovascular Disease
Apovian, C. M., & Gokce, N. (2012) · Circulation · doi:10.1161/circulationaha.111.022541 · Cited by 112
Pawar, R. S., & Grundel, E. (2016) · Drug Testing and Analysis · doi:10.1002/dta.1980 · Cited by 108
Managing obesity in primary care practice: a narrative review
Carvajal, R., Wadden, T. A., Tsai, A. G., Peck, K., & Moran, C. H. (2013) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12004 · Cited by 108
A review of therapeutic options for managing the metabolic aspects of polycystic ovary syndrome
Abdalla, M. A., Deshmukh, H., Atkin, S. L., & Sathyapalan, T. (2020) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018820938305 · Cited by 115
Food and Drug Administration's Obesity Drug Guidance Document: A Short History
Colman, E. (2012) · Circulation · doi:10.1161/circulationaha.111.028381 · Cited by 101
Current status of drug screening and disease modelling in human pluripotent stem cells
Rajamohan, D., Matsa, E., Kalra, S., Crutchley, J., Patel, A. K., George, V. T., & Denning, C. N. (2012) · BioEssays · doi:10.1002/bies.201200053 · Cited by 104
Weight management in obesity – past and present
Haslam, D. B. (2016) · International Journal of Clinical Practice · doi:10.1111/ijcp.12771 · Cited by 107
Fox, K. M., Michel Komajda, N., Ford, I., Robertson, M., Böhm, M., BORER, J. S., Steg, P. G., Tavazzi, L., Tendera, M., Ferrari, R., et al. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht101 · Cited by 95
Three-Year Outcomes of Bariatric Surgery in Patients With Obesity and Hypertension
Schiavon, C. A., Bhatt, D. L., Ikeoka, D., Santucci, E. V., Santos, R. N., Damiani, L. P., de Oliveira, J. D., Machado, R. H. V., Halpern, H., Monteiro, F. L. J., et al. (2020) · Annals of Internal Medicine · doi:10.7326/m19-3781 · Cited by 98
Weight loss interventions for chronic asthma
Adeniyi, F. B., & Young, T. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009339.pub2 · Cited by 97
Terranova, C. O., Brakenridge, C. L., Lawler, S. P., Eakin, E. G., & Reeves, M. M. (2015) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12430 · Cited by 94
Pharmacotherapy for obesity: novel agents and paradigms
Manning, S., Pucci, A. B. F., & Finer, N. (2014) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622314522848 · Cited by 99
Self-citationHeart rate: a forgotten link in coronary artery disease?
Fox, K. M., & Ferrari, R. (2011) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2011.58 · Cited by 91
Michos, E. D., López-Jiménez, F. A., & Gulati, M. (2023) · Journal of the American Heart Association · doi:10.1161/jaha.122.029282 · Cited by 97
Cardiovascular Risk-Benefit Profile of Sibutramine
Scheen, A. J. (2010) · American Journal of Cardiovascular Drugs · doi:10.2165/11584800-000000000-00000 · Cited by 89
All-Cause and Cause-Specific Mortality Associated with Bariatric Surgery: A Review
Adams, T. D., Mehta, T. S., Davidson, L. E., & Hunt, S. C. (2015) · Current Atherosclerosis Reports · doi:10.1007/s11883-015-0551-4 · Cited by 90
Management of Obesity in Cardiovascular Practice
Després, J.-P., Carpentier, A. C., Tchernof, A., Neeland, I. J., & Poirier, P. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.05.035 · Cited by 87
Incidence of Cancer Following Bariatric Surgery: Systematic Review and Meta-analysis
Casagrande, D. S., Rosa, D. D., Umpierre, D., Sarmento, R. A., Rodrigues, C. G., & Schaan, B. D. (2014) · Obesity Surgery · doi:10.1007/s11695-014-1276-0 · Cited by 87
Zhou, Y.-H., Ma, X.-Q., Wu, C., Lu, J., Zhang, S.-S., Guo, J., Wu, S.-Q., Ye, X.-F., Xu, J.-F., & He, J. (2012) · PLoS ONE · doi:10.1371/journal.pone.0039062 · Cited by 84
Garvey, W. T. (2013) · Endocrine Practice · doi:10.4158/ep13263.ra · Cited by 85
Acute Coronary Syndrome and Khat Herbal Amphetamine Use
Ali, W. M., Habib, K. F. A., Al‐Motarreb, A., Singh, R., Hersi, A. S., Faleh, H. A., Asaad, N., Saif, S. A., Almahmeed, W. A., Sulaiman, K., et al. (2011) · Circulation · doi:10.1161/circulationaha.111.039768 · Cited by 83
Ebling, F. J. P. (2014) · Hormones and Behavior · doi:10.1016/j.yhbeh.2014.03.009 · Cited by 82
Obesity management: what brings success?
Lagerros, Y. T., & Rössner, S. (2012) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x12459413 · Cited by 90
Boido, A., Ceriani, V., Cetta, F., Lombardi, F., & Pontiroli, A. E. (2015) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2015.01.011 · Cited by 80
Perspectives on Treatment for Nonalcoholic Steatohepatitis
Lassailly, G., Caiazzo, R. J., Pattou, F. N., & Mathurin, P. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.03.004 · Cited by 87
Pharmacotherapy for childhood obesity: present and future prospects
Sherafat‐Kazemzadeh, R., Yanovski, S. Z., & Yanovski, J. A. (2012) · International Journal of Obesity · doi:10.1038/ijo.2012.144 · Cited by 83
5‐Hydroxytryptamine Medications for the Treatment of Obesity
Burke, L. K., & Heisler, L. K. (2015) · Journal of Neuroendocrinology · doi:10.1111/jne.12287 · Cited by 82
Management of Dyslipidemia in Patients with Hypertension, Diabetes, and Metabolic Syndrome
Srikanth, S., & DEEDWANIA, P. C. (2016) · Current Hypertension Reports · doi:10.1007/s11906-016-0683-0 · Cited by 86
Weight-Reducing Side Effects of the Antiepileptic Agents Topiramate and Zonisamide
Antel, J., & Hebebrand, J. (2011) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-24716-3_20 · Cited by 79
Phattanawasin, P., Sotanaphun, U., Sukwattanasinit, T., Akkarawaranthorn, J., & Kitchaiya, S. (2012) · Forensic Science International · doi:10.1016/j.forsciint.2011.12.004 · Cited by 79
New Medications for Treatment of Obesity: Metabolic and Cardiovascular Effects
Pucci, A. B. F., & Finer, N. (2014) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2014.11.010 · Cited by 81
Self-citationEpigenetic Regulation of Adipogenesis in Development of Metabolic Syndrome
Pant, R., Firmal, P., Shah, V. K., Alam, A., & Chattopadhyay, S. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.619888 · Cited by 83
Randomized Trial of Effect of Bariatric Surgery on Blood Pressure After 5 Years
Schiavon, C. A., Cavalcanti, A. B., de Oliveira, J. D., Machado, R. H. V., Santucci, E. V., Santos, R. N., Oliveira, J. S., Damiani, L. P., Paranhos, D. J. C., Halpern, H., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.11.032 · Cited by 83
Fiedorowicz, J. G., Miller, D. D., Bishop, J. R., Calarge, C. A., Ellingrod, V. L., & Haynes, W. G. (2012) · Current Psychiatry Reviews · doi:10.2174/157340012798994867 · Cited by 82
Managing obesity in primary care practice: an overview with perspective from the POWER-UP study
Wadden, T. A., Volger, S., Tsai, A. G., Sarwer, D. B., Berkowitz, R. I., Diewald, L. K., Carvajal, R., Moran, C. H., & Vetter, M. L. (2013) · International Journal of Obesity · doi:10.1038/ijo.2013.90 · Cited by 80
Andersson, C., Gaal, L. V., Caterson, I. D., Weeke, P. E., James, W. P. T., Couthino, W., Finer, N., Sharma, A. M., Maggioni, A. P., & Torp-Pedersen, C. T. (2012) · Diabetologia · doi:10.1007/s00125-012-2584-3 · Cited by 77
Self-citationTolerability and Safety of the New Anti-Obesity Medications
Hainer, V., & Aldhoon-Hainerová, I. (2014) · Drug Safety · doi:10.1007/s40264-014-0206-3 · Cited by 76
Cardiovascular outcome trials in obesity: A review
Wilding, J. P. H., & Jacob, S. (2021) · Obesity Reviews · doi:10.1111/obr.13112 · Cited by 75
Present and Future: Pharmacologic Treatment of Obesity
Glandt, M., & Raz, I. (2011) · Journal of Obesity · doi:10.1155/2011/636181 · Cited by 81
Pharmacological management of binge eating disorder: current and emerging treatment options
McElroy, S., Guerdjikova, A. I., Mori, N., & O’Melia, A. (2012) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s25574 · Cited by 74
Papamargaritis, D., le Roux, C. W., Holst, J. J., & Davies, M. J. (2024) · Cardiovascular Research · doi:10.1093/cvr/cvac176 · Cited by 73
Ross, R., Lam, M. Y., Blair, S., Church, T., Godwin, M., Hotz, S., Johnson, A. Y., Katzmarzyk, P., Lévesque, L., & Macdonald, S. (2012) · Archives of Internal Medicine · doi:10.1001/archinternmed.2011.1972 · Cited by 75
Farina, M. G., Baratta, R., Nigro, A., Vinciguerra, F., Puglisi, C., Schembri, R., Virgilio, C. M., Vigneri, R., & Frittitta, L. (2011) · Obesity Surgery · doi:10.1007/s11695-011-0514-y · Cited by 72
Carneiro, G., & Zanella, M. T. (2018) · Metabolism · doi:10.1016/j.metabol.2018.03.008 · Cited by 71
Hypothalamic obesity: prologue and promise
Abuzzahab, M. J., Roth, C. L., & Shoemaker, A. H. (2019) · Hormone Research in Paediatrics · doi:10.1159/000496564 · Cited by 71
Diabetes and cardiovascular disease: inter-relation of risk factors and treatment
Sharma, A., Mittal, S., Aggarwal, R., & Chauhan, M. K. (2020) · Future Journal of Pharmaceutical Sciences · doi:10.1186/s43094-020-00151-w · Cited by 83
Self-citationLong-term effects of weight-reducing drugs in people with hypertension
Siebenhofer, A., Winterholer, S., Jeitler, K., Horvath, K., Berghold, A., Krenn, C., & Semlitsch, T. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007654.pub5 · Cited by 70
Combination therapy with naltrexone and bupropion for obesity
Billes, S. K., & Greenway, F. L. (2011) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2011.591382 · Cited by 74
Emerging techniques for determining the quality and safety of tea products: A review
Yu, X., Sun, D., & He, Y. (2020) · Comprehensive Reviews in Food Science and Food Safety · doi:10.1111/1541-4337.12611 · Cited by 73
Zhao, J., & Grant, S. F. A. (2011) · Journal of Obesity · doi:10.1155/2011/845148 · Cited by 75
Ahmad, N. N., Robinson, S., Kennedy‐Martin, T., Poon, J. L., & Kan, H. (2021) · Obesity Reviews · doi:10.1111/obr.13326 · Cited by 69
Grilo, C. M., Masheb, R. M., White, M. A., Gueorguieva, R. V., Barnes, R. D., Walsh, B. T., McKenzie, K. C., Genao, I., & Garcia, R. L. (2014) · Behaviour Research and Therapy · doi:10.1016/j.brat.2014.04.002 · Cited by 72
Bays, H. E., Fitch, A., Christensen, S., Burridge, K., & Tondt, J. (2022) · Obesity Pillars · doi:10.1016/j.obpill.2022.100018 · Cited by 68
Appetite- and Weight-Regulating Neuroendocrine Circuitry in Hypothalamic Obesity
Gan, H., Cerbone, M., & Dattani, M. (2023) · Endocrine Reviews · doi:10.1210/endrev/bnad033 · Cited by 75
Uric Acid as a Risk Factor for Cardiovascular Disease and Mortality in Overweight/Obese Individuals
Skak-Nielsen, H., Torp-Pedersen, C. T., Finer, N., Caterson, I. D., Gaal, L. V., James, W. P. T., Maggioni, A. P., Sharma, A. M., Coutinho, W. F., & Andersson, C. (2013) · PLoS ONE · doi:10.1371/journal.pone.0059121 · Cited by 68
Self-citationA Comprehensive Updated Review of Pharmaceutical and Nonpharmaceutical Treatment for NAFLD
Hossain, N., Kanwar, P., & Mohanty, S. R. (2016) · Gastroenterology Research and Practice · doi:10.1155/2016/7109270 · Cited by 70
New and Emerging Drug Molecules Against Obesity
George, M., Rajaram, M., & Shanmugam, E. (2013) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248413501017 · Cited by 68
An evaluation of liraglutide including its efficacy and safety for the treatment of obesity
Lin, C.-H., Shao, L., Zhang, Y.-M., Tu, Y.-J., Zhang, Y., Tomlinson, B., Chan, P., & Liu, Z. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1695779 · Cited by 65
5-HT2C Receptor Agonists and the Control of Appetite
Halford, J. C. G., & Harrold, J. A. (2011) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-24716-3_16 · Cited by 69
Treatment of Obesity in Children and Adolescents
Matson, K. L., & Fallon, R. M. (2012) · The Journal of Pediatric Pharmacology and Therapeutics · doi:10.5863/1551-6776-17.1.45 · Cited by 67
The limits and challenges of antiobesity pharmacotherapy
Gadde, K. M., & Atkins, K. D. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1748599 · Cited by 65
Maciá, M. A., de Abajo, F. J., Roberts, G., Slattery, J., Thakrar, B. T., & Wisniewski, A. F. Z. (2015) · Drug Safety · doi:10.1007/s40264-015-0351-3 · Cited by 65
Antidepressants and cardiovascular adverse events: A narrative review.
Nezafati, M. H., Vojdanparast, M., & Nezafati, P. (2015) · Europe PMC (PubMed Central) · Cited by 63
Leiter, L. A., FITCHETT, D. H., Gilbert, R. E., Gupta, M., Mancini, G. B. J., McFarlane, P. A., Ross, R., Teoh, H., Verma, S., Anand, S. S., et al. (2011) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2011.01.016 · Cited by 70
Self-citationManagement of nonalcoholic fatty liver disease: An evidence-based clinical practice review
Arab, J. P. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i34.12182 · Cited by 66
Intestinal removal of free fatty acids from hosts by Lactobacilli for the treatment of obesity
Chung, H., Yu, J. G., Lee, I., Liu, M., Shen, Y., Sharma, S. P., Jamal, M. A. H. M., Yoo, J., Kim, H., & Hong, S. (2015) · FEBS Open Bio · doi:10.1002/2211-5463.12024 · Cited by 68
Recognizing Binge-Eating Disorder in the Clinical Setting
Kornstein, S. G., Kunovac, J. L., Herman, B. K., & Culpepper, L. (2016) · The Primary Care Companion For CNS Disorders · doi:10.4088/pcc.15r01905 · Cited by 69
Luo, H., Ming, J., Lian, G., Liu, Q., Shi, M., Li, T. Y., Song, L., Ye, J., He, Y., Yao, L., et al. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.02.021 · Cited by 65
Effects of Norepinephrine Reuptake Inhibition on Postural Tachycardia Syndrome
Green, E. A., Raj, V., Shibao, C. A., Biaggioni, I., Black, B. K., Dupont, W. D., Robertson, D., & Raj, S. R. (2013) · Journal of the American Heart Association · doi:10.1161/jaha.113.000395 · Cited by 64
Safety and Efficacy of Lorcaserin: A Combined Analysis of the BLOOM and BLOSSOM Trials
Aronne, L. J., Shanahan, W. R., Fain, R., Glicklich, A., Soliman, W., Li, Y., & Smith, S. R. (2014) · Postgraduate Medicine · doi:10.3810/pgm.2014.10.2817 · Cited by 64
Can medical therapy mimic the clinical efficacy or physiological effects of bariatric surgery?
Miras, A. D., & le Roux, C. W. (2013) · International Journal of Obesity · doi:10.1038/ijo.2013.205 · Cited by 65
Effect of acupuncture and intervention types on weight loss: a systematic review and meta‐analysis
Kim, S., In-Soo, S., & Park, Y.-J. (2018) · Obesity Reviews · doi:10.1111/obr.12747 · Cited by 67
What is the prognosis for new centrally-acting anti-obesity drugs?
Heal, D. J., Gosden, J., & Smith, S. L. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.01.017 · Cited by 64
Vickers, S. P., Cheetham, S. C., Headland, K. R., Dickinson, K., Grempler, R., Mayoux, E., Mark, M., & Klein, T. (2014) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s58786 · Cited by 62
Serotonergic Anti-Obesity Agents
Halford, J. C. G., Boyland, E. J., Lawton, C. L., Blundell, J. E., & Harrold, J. A. (2011) · Drugs · doi:10.2165/11596680-000000000-00000 · Cited by 62
The new era of drug therapy for obesity: the evidence and the expectations
Jones, B. J., & Bloom, S. R. (2015) · Drugs · doi:10.1007/s40265-015-0410-1 · Cited by 58
Current challenges in the detection and analysis of falsified medicines
Hart, I. M. E. B.-'., Ohana, D., & Venhuis, B. J. (2021) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2021.113948 · Cited by 62
New Serotonin-Norepinephrine Reuptake Inhibitors and Their Anesthetic and Analgesic Considerations
Fanelli, D., Weller, G. E. R., & Liu, H. (2021) · Neurology International · doi:10.3390/neurolint13040049 · Cited by 62
Strategies for preventing type 2 diabetes: an update for clinicians
Khavandi, K., Amer, H., Ibrahim, B., & Brownrigg, J. R. W. (2013) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622313494986 · Cited by 62
Kumar, V., Singh, D. D., Lakhawat, S. S., Yasmeen, N., Pandey, A., & Singla, R. K. (2022) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2022/6852276 · Cited by 64
Assessment of Endothelial Dysfunction in Childhood Obesity and Clinical Use
Bruyndonckx, L., Hoymans, V. Y., Craenenbroeck, A. H. V., Vissers, D. K., Vrints, C. J., Ramet, J., & Conraads, V. M. (2013) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2013/174782 · Cited by 66
A new approach to determining pharmacologic adulteration of herbal weight loss products
de Carvalho, L. M., Cohen, P. A., Silva, C. V., Moreira, A. P., Falcão, T. M., Molin, T. R. D., Zemolin, G. M., & Martini, M. (2012) · Food Additives & Contaminants Part A · doi:10.1080/19440049.2012.706834 · Cited by 61
Chazova, I. E., & Schlaich, M. P. (2013) · International Journal of Hypertension · doi:10.1155/2013/541689 · Cited by 60
Morus alba (mulberry), a natural potent compound in management of obesity
Mahboubi, M. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104341 · Cited by 60
The GLP-1 agonist, liraglutide, as a pharmacotherapy for obesity
Crane, J. D., & McGowan, B. M. (2015) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622315620180 · Cited by 67
Carlsson, A. C., Risérus, U., Engström, G., Ärnlöv, J., Melander, O., Leander, K., Gigante, B., Hellénius, M.-L., & Fairé, U. D. (2013) · International Journal of Obesity · doi:10.1038/ijo.2013.46 · Cited by 58
Alfaris, N., Wadden, T. A., Sarwer, D. B., Diwald, L., Volger, S., Hong, P., Baxely, A., Minnick, A. M., Vetter, M. L., Berkowitz, R. I., et al. (2015) · Obesity · doi:10.1002/oby.20996 · Cited by 57
Pharmacotherapy for Patients with Obesity
Gadde, K. M., Apolzan, J. W., & Berthoud, H. (2017) · Clinical Chemistry · doi:10.1373/clinchem.2017.272815 · Cited by 57
Therapeutic advances in obesity management: an overview of the therapeutic interventions
Roomy, M. A., Hussain, K., Behbehani, H. M., Abu-Farha, J., Al-Harris, R., Ambi, A. M., Abdalla, M. A., Al‐Mulla, F., Abu‐Farha, M., & Abubaker, J. A. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1364503 · Cited by 67
Obesity and weight management in the elderly: A focus on men
Han, T. S., Wu, F. C. W., & Lean, M. E. J. (2013) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2013.04.012 · Cited by 57
Sibutramine on Cardiovascular Outcome
Scheen, A. J. (2011) · Diabetes Care · doi:10.2337/dc11-s205 · Cited by 55
Hsieh, C., Ho, M.-Y., Wen, M., Chen, C., Hsieh, M., Lin, C., Yeh, J., Tsai, M., Yang, C., Wu, V. C., et al. (2018) · International Journal of Cardiology · doi:10.1016/j.ijcard.2017.11.072 · Cited by 55
Pharmacotherapy for obesity: moving towards efficacy improvement
Coutinho, W. F., & Halpern, B. (2024) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-023-01233-4 · Cited by 64
Self-citationBredella, M. A., Lin, E., Brick, D. J., Gerweck, A. V., Harrington, L. M., Torriani, M., Thomas, B. J., Schoenfeld, D., Breggia, A., Rosen, C. J., et al. (2012) · European Journal of Endocrinology · doi:10.1530/eje-11-1068 · Cited by 53
Heart Rate and the Cardiometabolic Risk
Palatini, P. (2013) · Current Hypertension Reports · doi:10.1007/s11906-013-0342-7 · Cited by 55
Magnusson, M., Hedblad, B., Engström, G., Persson, M., Nilsson, P. M., & Melander, O. (2013) · Journal of Internal Medicine · doi:10.1111/joim.12051 · Cited by 55
van de Ven, K., Mulrooney, K. J. D., & McVeigh, J. (2019) · Routledge eBooks · doi:10.4324/9781315148328 · Cited by 55
Why are anti-obesity drugs stigmatized?
Halpern, B., & Halpern, A. (2014) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2015.995088 · Cited by 55
Metadata
- Authors
- James, W. P. T., Caterson, I. D., Coutinho, W., Finer, N., Van Gaal, L. F., Maggioni, A. P., Torp-Pedersen, C., Sharma, A. M., Shepherd, G. M., Rode, R. A., & Renz, C. L.
- Affiliations
- London School of Hygiene & Tropical Medicine (GB)
- The University of Sydney (AU)
- Pontifícia Universidade Católica do Rio de Janeiro (BR)
- University College London (GB)
- Associazione Nazionale Medici Cardiologi Ospedalieri (IT)
- Gentofte Hospital (DK)
- University of Alberta (CA)
- Abbott (United States) (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2010-09-02
- Volume
- 363
- Issue
- 10
- Pages
- 905-917
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2119779723
- Cited by
- 943
- References
- 33
- Citations by year
- 2026: 27 · 2025: 43 · 2024: 50 · 2023: 40 · 2022: 35 · 2021: 50 · 2020: 45 · 2019: 36 · 2018: 54 · 2017: 38 · 2016: 63 · 2015: 69 · 2014: 75 · 2013: 91 · 2012: 93
- FWCI
- 75.02
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- LSHTM Research Online (London School of Hygiene and Tropical Medicine) (acceptedVersion)
- UCrea (University of Cantabria) (submittedVersion, cc-by)
- UWA Profiles and Research Repository (UWA) (submittedVersion)
- CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion)
- UCL Discovery (University College London) (submittedVersion)
- University of Debrecen Electronic Archive (University of Debrecen) (submittedVersion, other-oa)
- ORBi (University of Liège) (submittedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Funders
- Abbott Laboratories
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Sanofi
- University of Cambridge
- Eisai
- Novo Nordisk
- Shionogi
- Servier
- Allergan
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
- Keywords
- sibutramine, cardiovascular outcomes, obesity, overweight, weight management, cardiovascular risk, myocardial infarction, stroke, cardiovascular mortality, type 2 diabetes, blood pressure, weight loss, older adults, drug safety, appetite suppressants, anti-obesity drugs, cardiovascular events, cardiovascular risk reduction, cardiovascular risk stratification
- MeSH terms
- Aged, Appetite Depressants, Blood Pressure, Cardiovascular Diseases, Cyclobutanes, Diabetes Mellitus, Type 2, Double-Blind Method, Female, Humans, Male, Middle Aged, Myocardial Infarction, Obesity, Stroke, Overweight, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
